10 mau huaʻōlelo āu e ʻike ai: Ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi

Anter

• Polokalamu make-ligand 1 (PD-L1)
• ʻO ka receptor ulu ulu Epidermal (EGFR)
• Hoʻololi T790M
• ʻO ka mea kāohi lāʻau ʻo Tyrosinse-kinase (TKI)
• Hoʻololi KRAS
• Anaplastic lymphoma kinase (ALK) hoʻololi
• Adenocarcinoma
• ʻO ke kinikini squamous (epidermoid)
• ʻO ke kinikini nui (ʻole)
• Immunotherapy

Hōʻike Overview

Inā ua ʻike ʻia ʻoe a ʻo kāu mea aloha paha, ʻo ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC) a me nā huaʻōlelo he nui e pili ana iā ia hiki ke luhi loa. Ke hoʻāʻo nei e hoʻomau me nā huaʻōlelo a kāu kauka i haʻi aku ai iā ʻoe he paʻakikī, keu hoʻi me ka hopena o ka hopena o ka maʻi ʻaʻai.

Eia he mau huaʻōlelo he 10 e ʻike e pili ana i ka NSCLC i hiki iā ʻoe ke hālāwai i kou hele ʻana ma o ka hoʻāʻo ʻana a me ka mālama ʻana.

Polokalamu make-ligand 1 (PD-L1)

Ke ana nei ʻo PD-L1 i ka pono o kekahi mau therapies i hoʻolālā ʻia (ʻo ka maʻamau maʻamau pale ʻia) no ka poʻe me NSCLC. Kōkua kēia i nā kauka e ʻōlelo i nā koho lapaʻau lālani ʻoi loa.

E hoʻi i ka panakō huaʻōlelo

ʻO ka receptor ulu ulu Epidermal (EGFR)

ʻO EGFR kahi ʻāpana e pili ana i ka ulu a me ka mahele o ka cell. Pili nā hoʻololi ʻana o kēia gen i ka maʻi ʻaʻai. Aia i ka hapalua o nā hihia maʻi ʻaʻaiā āpau i loaʻa kahi genation mutation i kēia manawa.

E hoʻi i ka panakō huaʻōlelo

Hoʻololi T790M

ʻO T790M kahi hoʻololi EGFR i ʻike ʻia ma kahi o ka hapalua o nā hihia NSCLC kūpaʻa lāʻau āpau. ʻO ke ʻano o ka hoʻololi ʻana he loli i nā amino acid, a pili ia i ka pane ʻana o kekahi i ka lāʻau.

E hoʻi i ka panakō huaʻōlelo

ʻO ka mea kāohi lāʻau ʻo Tyrosinse-kinase (TKI)

He ʻano mālama kolohe ʻo TKI therapy no NSCLC e ālai ana i ka hana o EGFR, ka mea hiki ke mālama i nā hunaola maʻi ʻaʻai mai ka ulu ʻana.

E hoʻi i ka panakō huaʻōlelo

Hoʻololi KRAS

Kōkua ka ʻohana KRAS i ka hoʻoponopono ʻana i ka mahele o ka pūnaewele. He ʻāpana ia o kahi hui o nā gen i kapa ʻia ʻo oncogenes. I ke ʻano o ka hoʻololi ʻana, hiki iā ia ke hoʻolilo i nā hunaola olakino i mau maʻi ʻaʻai. ʻIke ʻia nā hoʻololi ʻana o ka ʻohana KRAS ma kahi o 15 a 25 pakeneka o nā hihia maʻi ʻaʻaiā āpau.

E hoʻi i ka panakō huaʻōlelo

Anaplastic lymphoma kinase (ALK) hoʻololi

ʻO kahi hoʻololi ALK kahi hoʻonohonoho hou o ka ʻāpana ALK. Loaʻa kēia hoʻololi ma kahi o 5 pākēneka o nā hihia NSCLC, ʻo ka mea maʻamau i nā mea me ka subenype adenocarcinoma o NSCLC. Mālama ka hoʻololi i ka ulu a pālahalaha ʻana o nā hunaola maʻi ʻaʻai.

E hoʻi i ka panakō huaʻōlelo

Adenocarcinoma

ʻO Adenocarcinoma kahi subtype o NSCLC. Mālama ʻo ia e ulu lohi ma mua o nā ʻano like ʻole o ka maʻi ʻaʻa maʻi, akā ʻokoʻa kēia. ʻO ia ka ʻano maʻamau o ke kanesa maʻi ʻaʻai i ʻike ʻia i nā mea puhipaka ʻole.

E hoʻi i ka panakō huaʻōlelo

ʻO ke kinikini squamous (epidermoid)

ʻO ke kinikini cell squamous kahi subtype o NSCLC. He nui ka poʻe me kēia subtype o ka maʻi ʻaʻai pūpū i kahi moʻolelo o ka puhipaka. Hoʻomaka ka maʻi ʻaʻai i nā hunaola squamous, ʻo ia nā hunaola i loko o nā alaloa māmā.

E hoʻi i ka panakō huaʻōlelo

ʻO ke kinikini nui (ʻole)

ʻO ka carcinoma nui pūnaewele kahi subtype o NSCLC i hiki ke hōʻike ʻia ma nā ʻāpana o ka akemāmā. ʻOi aku ka paʻakikī o ka mālama ʻana no ka mea ulu a pālahalaha koke. Loaʻa iā ia ma kahi o 10 a 15 paha pākēneka o nā maʻi ʻaʻai.

E hoʻi i ka panakō huaʻōlelo

Immunotherapy

ʻO Immunotherapy kahi lapaʻau hou loa no ka maʻi ʻaʻai e hoʻohana ai i ka ʻōnaehana pale o ke kanaka e kōkua ai i ke kino e hoʻouka i nā hunaola maʻi ʻaʻai. Hiki ke hoʻohana ʻia e mālama i kekahi ʻano o ka NSCLC, keu hoʻi i ka poʻe i hoʻi ka maʻi ʻaʻai ma hope o ka chemotherapy a i ʻole ka lāʻau ʻē aʻe.

E hoʻi i ka panakō huaʻōlelo